This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website, you indicate your consent. Cookie Policy
It’s unclear whether the lack of availability is a short-term consequence of the J&J hiatus while administrators ramp up again, or a matter of dwindling supplies from the manufacturer.
A Chesapeake resident is one of the rare people to experience a skin reaction spanning her body after receiving a COVID-19 vaccine. Her rash — a measles-like explosion — caused her severe burning, but is otherwise considered harmless.
As of last week, about 2 million Virginians had been fully vaccinated against the coronavirus. But public health experts say there's still a long way to herd immunity, and another surge may be around the bend.
The decision follows a federal recommendation to “pause” J&J administration while the U.S. investigates clots in six women that occurred 6 to 13 days after vaccination.
Instead of receiving a previously expected 125,000 doses from the maker, the state will get just 15,000 next week, said Dr. Parham Jaberi, Virginia Department of Health’s chief deputy commissioner for public health preparedness.